| Citation: |
YE Hunan, SHEN Yulan, LI Jiaying, ZHOU Huanhuan, ZHANG Fanrong, WANG Xiaojia. Research Advancements of Antibody-Drug Conjugates in Breast Cancer at 2024 ASCO Annual Meeting[J]. Cancer Research on Prevention and Treatment, 2025, 52(3): 185-192. DOI: 10.3971/j.issn.1000-8578.2025.24.0999
|
The 2024 American Society of Clinical Oncology (ASCO) Annual Meeting was held in Chicago, the United States, from May 31 to June 4 in 2024. In recent years, antibody-drug conjugates (ADCs) have become one of the most popular targeted therapies because of their high specificity, efficacy, and low toxicity, making them a focal point in this ASCO meeting. Currently, over 100 ADCs are under investigation, demonstrating the considerable development potential of ADCs in the field of targeted cancer therapy. The aforementioned conference reported several recent research advancements regarding ADCs for the treatment of breast cancer (BC). This review summarizes the latest progress of ADCs in BC treatment discussed at the conference.
Competing interests: The authors declare that they have no competing interests.
| [1] |
von Minckwitz G, Huang CS, Mano MS, et al. Trastuzumab Emtansine for Residual Invasive HER2-Positive Breast Cancer[J]. N Engl J Med, 2019, 380(7): 617-628. doi: 10.1056/NEJMoa1814017
|
| [2] |
Chumsri S, Giri S, Ness A, et al. Safety run-in phase of the multi-epitope HER2 peptide vaccine in combination with trastuzumab emtansine in HER2-positive breast cancer with residual disease after neoadjuvant chemotherapy[J]. J Clin Oncol, 2024, 42(16_suppl): 550. doi: 10.1200/JCO.2024.42.16_suppl.550
|
| [3] |
Knutson KL, Block MS, Norton N, et al. Rapid Generation of Sustainable HER2-specific T-cell Immunity in Patients with HER2 Breast Cancer using a Degenerate HLA Class II Epitope Vaccine[J]. Clin Cancer Res, 2020, 26(5): 1045-1053. doi: 10.1158/1078-0432.CCR-19-2123
|
| [4] |
Krop IE, Im SA, Barrios C, et al. Trastuzumab Emtansine Plus Pertuzumab Versus Taxane Plus Trastuzumab Plus Pertuzumab After Anthracycline for High-Risk Human Epidermal Growth Factor Receptor 2-Positive Early Breast Cancer: The Phase Ⅲ KAITLIN Study[J]. J Clin Oncol, 2022, 40(5): 438-448. doi: 10.1200/JCO.21.00896
|
| [5] |
Harbeck N, Nitz UA, Christgen M, et al. De-Escalated Neoadjuvant Trastuzumab-Emtansine With or Without Endocrine Therapy Versus Trastuzumab With Endocrine Therapy in HR+/HER2+ Early Breast Cancer: 5-Year Survival in the WSG-ADAPT-TP Trial[J]. J Clin Oncol, 2023, 41(22): 3796-3804. doi: 10.1200/JCO.22.01816
|
| [6] |
Hurvitz SA, Peddi PF, Tetef ML, et al. TRIO-US B-12 TALENT: Neoadjuvant trastuzumab deruxtecan with or without anastrozole for HER2-low, HR+early stage breast cancer[J]. J Clin Oncol, 2023, 39(15_suppl): TPS603.
|
| [7] |
Harbeck N, Braun M, Gluz O, et al. Neoadjuvant dynamic marker-adjusted personalized therapy comparing trastuzumab-deruxtecan versus pacli-/docetaxel + carboplatin + trastuzumab + pertuzumab in HER2+ early breast cancer: WSG-ADAPT-HER2-IV[J]. J Clin Oncol, 2024, 12(16_suppl): TPS631.
|
| [8] |
Fuentes-Antrás J, Genta S, Vijenthira A, et al. Antibody-drug conjugates: in search of partners of choice[J]. Trends Cancer, 2023, 9(4): 339-354. doi: 10.1016/j.trecan.2023.01.003
|
| [9] |
Shatsky RA, Trivedi MS, Omene CO, et al. Rates of pathologic complete response (pCR) after datopotamab deruxtecan (Dato) plus durvalumab (Durva) in the neoadjuvant setting: Results from the I-SPY2.2 trial[J]. J Clin Oncol, 2024, 42(17_suppl): LBA501. doi: 10.1200/JCO.2024.42.17_suppl.LBA501
|
| [10] |
Wolf DM, Yau C, Wulfkuhle J, et al. Redefining breast cancer subtypes to guide treatment prioritization and maximize response: Predictive biomarkers across 10 cancer therapies[J]. Cancer Cell, 2022, 40(6): 609-623. e6.
|
| [11] |
Pusztai L, Yau C, Wolf DM, et al. Durvalumab with olaparib and paclitaxel for high-risk HER2-negative stage Ⅱ/Ⅲ breast cancer: Results from the adaptively randomized I-SPY2 trial[J]. Cancer Cell, 2021, 39(7): 989-998. e5.
|
| [12] |
Meisel JL, Khoury K, Chien AJ, et al. Rates of pathologic complete response (pCR)after neoadjuvant datopotamab deruxtecan (Dato): Results from the I-SPY2.2 trial[J]. J Clin Oncol, 2024, 42(17_suppl): LBA509. doi: 10.1200/JCO.2024.42.17_suppl.LBA509
|
| [13] |
Hamilton EP, Hurvitz SA, Im S-A, et al. Trastuzumab deruxtecan (T-DXd) vs trastuzumab emtansine (T-DM1) in patients (pts) with HER2+ metastatic breast cancer (mBC): Updated survival results of DESTINY-Breast03[J]. J Clin Oncol, 2024, 42(16_suppl): 1025. doi: 10.1200/JCO.2024.42.16_suppl.1025
|
| [14] |
Cortés J, Kim SB, Chung WP, et al. Trastuzumab Deruxtecan versus Trastuzumab Emtansine for Breast Cancer[J]. N Engl J Med, 2022, 386(12): 1143-1154. doi: 10.1056/NEJMoa2115022
|
| [15] |
Botticelli A, Fabi A, Rossi A, et al. Trastuzumab deruxtecan in patients with breast cancer with brain metastases: The DE-REAL study[J]. J Clin Oncol, 2024, 42(16_suppl): 1032. doi: 10.1200/JCO.2024.42.16_suppl.1032
|
| [16] |
Saura C, Cortés J, Modi S, et al. Pooled analysis by best confirmed response to trastuzumab deruxtecan (T-DXd) in patients (pts) with HER2+ metastatic breast cancer (mBC) from DESTINY-Breast-01, -02, and -03[J]. J Clin Oncol, 2024, 42(16_suppl): 1023. doi: 10.1200/JCO.2024.42.16_suppl.1023
|
| [17] |
Curigliano G, Hu XC, Dent RA, et al. Trastuzumab deruxtecan (T-DXd) vs physician’s choice of chemotherapy (TPC) in patients (pts) with hormone receptor-positive (HR+), human epidermal growth factor receptor 2 (HER2)-low or HER2-ultralow metastatic breast cancer (mBC) with prior endocrine therapy (ET): Primary results from DESTINY-Breast06 (DB-06)[J]. J Clin Oncol, 2024, 42(17_suppl): LBA1000. doi: 10.1200/JCO.2024.42.17_suppl.LBA1000
|
| [18] |
Andre FA, Hamilton EP, Loi S, et al. DESTINY-Breast07: Dose-expansion interim analysis of T-DXd monotherapy and T-DXd + pertuzumab in patients with previously untreated HER2+ mBC[J]. J Clin Oncol, 2024, 42(16_suppl): 1009. doi: 10.1200/JCO.2024.42.16_suppl.1009
|
| [19] |
Cheng A, Frank S, Baines K, et al. Real world experience of trastuzumab deruxtecan for the treatment of metastatic breast cancer in the UK[J]. J Clin Oncol, 2024, 42(16_suppl): 1024. doi: 10.1200/JCO.2024.42.16_suppl.1024
|
| [20] |
Tarantino P, Lee D, Foldi J, et al. Outcomes with trastuzumab deruxtecan (T-DXd) by HER2 status and line of treatment in a large real-world database of patients with metastatic breast cancer[J]. J Clin Oncol, 2024, 42(16_suppl): 1077. doi: 10.1200/JCO.2024.42.16_suppl.1077
|
| [21] |
Shimomura A, Tamura K, Tanaka K, et al. A randomized phase Ⅲ study comparing trastuzumab emtansine with trastuzumab, pertuzumab and docetaxel in elderly patients with advanced stage HER2-positive breast cancer: Japan Clinical Oncology Group Study (JCOG1607, HERB TEA study)[J]. Jpn J Clin Oncol, 2021, 51(9): 1471-1474. doi: 10.1093/jjco/hyab101
|
| [22] |
Shimomura A, Tamura K, Sasaki K, et al. The subgroup analysis by age and geriatric assessment in a phase Ⅲ study comparison of trastuzumab emtansine with trastuzumab, pertuzumab, and docetaxel in older patients with advanced stage HER2-positive breast cancer (JCOG1607 HERB TEA study)[J]. J Clin Oncol, 2024, 42(16_suppl): 1031. doi: 10.1200/JCO.2024.42.16_suppl.1031
|
| [23] |
Zhang J, Ji D, Shen W, et al. Phase I Trial of a Novel Anti-HER2 Antibody-Drug Conjugate, ARX788, for the Treatment of HER2-Positive Metastatic Breast Cancer[J]. Clin Cancer Res, 2022, OF1-OF10.
|
| [24] |
Bardia A, Hurvitz SA, Tolaney SM, et al. Sacituzumab Govitecan in Metastatic Triple-Negative Breast Cancer[J]. N Engl J Med, 2021, 384(16): 1529-1541. doi: 10.1056/NEJMoa2028485
|
| [25] |
Rugo HS, Bardia A, Marmé F, et al. Overall survival with sacituzumab govitecan in hormone receptor-positive and human epidermal growth factor receptor 2-negative metastatic breast cancer (TROPiCS-02): a randomised, open-label, multicentre, phase 3 trial[J]. Lancet, 2023, 402(10411): 1423-1433. doi: 10.1016/S0140-6736(23)01245-X
|
| [26] |
Garrido-Castro AC, Kim SE, Desrosiers J, et al. SACI-IO HR+: A randomized phase Ⅱ trial of sacituzumab govitecan with or without pembrolizumab in patients with metastatic hormone receptor-positive/HER2-negative breast cancer[J]. J Clin Oncol, 2024, 42(17_suppl 17): 1004.
|
| [27] |
Ahmed KA, Kim Y, DeJesus M, et al. Phase Ⅰ/Ⅱ study of stereotactic radiation and sacituzumab govitecan with zimberelimab in the management of metastatic triple negative breast cancer with brain metastases[J]. J Clin Oncol, 2024, 42(16_suppl): TPS1140. doi: 10.1200/JCO.2024.42.16_suppl.TPS1140
|
| [28] |
Bardia A, Sun S, Thimmiah N, et al. Antibody-Drug Conjugate Sacituzumab Govitecan Enables a Sequential TOP1/PARP Inhibitor Therapy Strategy in Patients with Breast Cancer[J]. Clin Cancer Res, 2024, 30(14): 2917-2924. doi: 10.1158/1078-0432.CCR-24-0428
|
| [29] |
Abelman RO, Spring L, Niemierko A, et al. Sequential combination of sacituzumab govitecan and talazoparib in metastatic triple negative breast cancer (mTNBC): Results from a phase Ⅱ study[J]. J Clin Oncol, 2024, 42(16_suppl): 1102. doi: 10.1200/JCO.2024.42.16_suppl.1102
|
| [30] |
Pernas S, Im S-A, Hattori M, et al. Datopotamab deruxtecan (Dato-DXd) vs. chemotherapy (CT) in previously treated inoperable or metastatic hormone receptor-positive, HER2-negative (HR+/HER2–) breast cancer (BC): Patient-reported outcomes (PROs) from the TROPION-Breast01 study[J]. J Clin Oncol, 2024, 42(16_suppl): 1006. doi: 10.1200/JCO.2024.42.16_suppl.1006
|
| [31] |
Khosravanian MJ, Mirzaei Y, Mer AH, et al. Nectin-4-directed antibody-drug conjugates (ADCs): Spotlight on preclinical and clinical evidence[J]. Life Sci, 2024, 352: 122910. doi: 10.1016/j.lfs.2024.122910
|
| [32] |
Giordano A, Awan AA, Bruce JY, et al. Enfortumab vedotin (EV) in triple-negative breast cancer (TNBC) and HR+/HER2- breast cancer (BC) cohorts of EV-202[J]. J Clin Oncol, 2024, 42(16_suppl): 1005. doi: 10.1200/JCO.2024.42.16_suppl.1005
|
| [33] |
Huppert LA, Mahtani R, Fisch SC, et al. Multicenter retrospective cohort study of the sequential use of the antibody-drug conjugates (ADCs) trastuzumab deruxtecan (T-DXd) and sacituzumab govitecan (SG) in patients with HER2-low metastatic breast cancer (MBC): Updated data and subgroup analyses by age, sites of disease, and use of intervening therapies[J]. J Clin Oncol, 2024, 42(16_suppl): 1083. doi: 10.1200/JCO.2024.42.16_suppl.1083
|
| [34] |
Mai N, Klar M, Ferraro E, et al. Real world outcomes of sequential ADC therapy in metastatic breast cancer: Patients treated with sacituzumab govitecan and trastuzumab deruxtecan[J]. J Clin Oncol, 2024, 42(16_suppl): 1085. doi: 10.1200/JCO.2024.42.16_suppl.1085
|
| [35] |
Tripathy D, Ali K, Agrawal L, et al. ACE-BREAST-03: A phase 2 trial evaluating ARX788, an anti-HER2 antibody drug conjugate (ADC), for the treatment of HER2+ metastatic breast cancer (mBC) in patients who have been previously treated with trastuzumab deruxtecan (T-DXd)[J]. J Clin Oncol, 2024, 42(16_suppl): TPS1123. doi: 10.1200/JCO.2024.42.16_suppl.TPS1123
|
This work is licensed under a Creative Commons Attribution 3.0 License.
Copyright © Editorial Department of Cancer Prevention Research 鄂公网安备 42011102005013号 鄂ICP备2022015867号
Supported by: Beijing Renhe Information Technology Co., Ltd. 
DownLoad: